Michael Deininger, MD, PhD

Dr. Deininger received his MD from the University of Würzburg Medical School, Germany and his PhD from Imperial College, London. His thesis work focused on signal transduction and the potential use of imatinib (Gleevec) as molecularly targeted therapy for chronic myeloid leukemia (CML), and contributed to the approval of imatinib for the treatment of CML. In 2002 he was recruited to the Division of Hematology and Medical Oncology at Oregon Health & Science University (OHSU). In 2007 he became the Head of the Hematologic Malignancies Section at OHSU. From 2010-2011 Dr. Deininger served as Chief of Hematology at the University of Utah, Senior Director for Transdisciplinary Research at Huntsman Cancer Institute, and Director of the Center of Excellence in Hematology and Hematologic Malignancies. In 2021 he became the Director of the Versiti Blood Research Institute, Executive VP for Research and a Professor of Medicine at the Medical College of Wisconsin. Throughout his career, Dr. Deininger lead a laboratory researching leukemia and oversaw clinical trials, while he maintained a clinical practice.